BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hempen M, Kopp HP, Elhenicky M, Höbaus C, Brix JM, Koppensteiner R, Schernthaner G, Schernthaner GH. YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obes Surg 2009;19:1557-63. [PMID: 19633900 DOI: 10.1007/s11695-009-9917-4] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Kyrgios I, Galli-Tsinopoulou A, Stylianou C, Papakonstantinou E, Arvanitidou M, Haidich AB. Elevated circulating levels of the serum acute-phase protein YKL-40 (chitinase 3-like protein 1) are a marker of obesity and insulin resistance in prepubertal children. Metabolism 2012;61:562-8. [PMID: 22036069 DOI: 10.1016/j.metabol.2011.09.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
2 Wang Q, Shen H, Min J, Gao Y, Liu K, Xi W, Yang J, Yin L, Xu J, Xiao J, Wang Z. YKL-40 is highly expressed in the epicardial adipose tissue of patients with atrial fibrillation and associated with atrial fibrosis. J Transl Med 2018;16:229. [PMID: 30111325 DOI: 10.1186/s12967-018-1598-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
3 Rathcke CN, Vestergaard H. YKL-40--an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8:61. [PMID: 19930630 DOI: 10.1186/1475-2840-8-61] [Cited by in Crossref: 115] [Cited by in F6Publishing: 115] [Article Influence: 8.8] [Reference Citation Analysis]
4 Schernthaner GH, Höbaus C, Brix J. YKL-40 and its complex association with metabolic syndrome, obesity, and cardiovascular disease. Anatol J Cardiol 2016;16:959. [PMID: 28005023 DOI: 10.14744/AnatolJCardiol.2016.22332] [Reference Citation Analysis]
5 Thomsen SB, Gjesing AP, Rathcke CN, Ekstrøm CT, Eiberg H, Hansen T, Pedersen O, Vestergaard H. Associations of the Inflammatory Marker YKL-40 with Measures of Obesity and Dyslipidaemia in Individuals at High Risk of Type 2 Diabetes. PLoS One 2015;10:e0133672. [PMID: 26197239 DOI: 10.1371/journal.pone.0133672] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
6 Egert S, Baxheinrich A, Lee-Barkey YH, Tschoepe D, Wahrburg U, Stratmann B. Effects of an energy-restricted diet rich in plant-derived α-linolenic acid on systemic inflammation and endothelial function in overweight-to-obese patients with metabolic syndrome traits. Br J Nutr 2014;112:1315-22. [PMID: 25180479 DOI: 10.1017/S0007114514002001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 2.9] [Reference Citation Analysis]
7 Thomsen SB, Rathcke CN, Jørgensen NB, Madsbad S, Vestergaard H. Effects of Roux-en-Y gastric bypass on fasting and postprandial levels of the inflammatory markers YKL-40 and MCP-1 in patients with type 2 diabetes and glucose tolerant subjects. J Obes 2013;2013:361781. [PMID: 24303210 DOI: 10.1155/2013/361781] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
8 Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Valentí V, Moncada R, Silva C, Salvador J, Frühbeck G. Peripheral mononuclear blood cells contribute to the obesity-associated inflammatory state independently of glycemic status: involvement of the novel proinflammatory adipokines chemerin, chitinase-3-like protein 1, lipocalin-2 and osteopontin. Genes Nutr 2015;10:460. [PMID: 25869413 DOI: 10.1007/s12263-015-0460-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
9 Prakash M, Bodas M, Prakash D, Nawani N, Khetmalas M, Mandal A, Eriksson C. Diverse pathological implications of YKL-40: Answers may lie in ‘outside-in’ signaling. Cellular Signalling 2013;25:1567-73. [DOI: 10.1016/j.cellsig.2013.03.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 5.9] [Reference Citation Analysis]
10 Xing S, Zheng X, Zeng T, Zeng MS, Zhong Q, Cao YS, Pan KL, Wei C, Hou F, Liu WL. Chitinase 3-like 1 secreted by peritumoral macrophages in esophageal squamous cell carcinoma is a favorable prognostic factor for survival. World J Gastroenterol 2017; 23(43): 7693-7704 [PMID: 29209110 DOI: 10.3748/wjg.v23.i43.7693] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
11 Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Izaguirre M, Hernández-Lizoain JL, Baixauli J, Martí P, Valentí V, Moncada R, Silva C, Salvador J, Frühbeck G. Increased Obesity-Associated Circulating Levels of the Extracellular Matrix Proteins Osteopontin, Chitinase-3 Like-1 and Tenascin C Are Associated with Colon Cancer. PLoS One 2016;11:e0162189. [PMID: 27612200 DOI: 10.1371/journal.pone.0162189] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
12 Zhao T, Su Z, Li Y, Zhang X, You Q. Chitinase-3 Like-protein-1 function and its role in diseases. Signal Transduct Target Ther. 2020;5:201. [PMID: 32929074 DOI: 10.1038/s41392-020-00303-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
13 Batinic K, Höbaus C, Grujicic M, Steffan A, Jelic F, Lorant D, Hörtenhuber T, Hoellerl F, Brix JM, Schernthaner G, Koppensteiner R, Schernthaner GH. YKL-40 is elevated in patients with peripheral arterial disease and diabetes or pre-diabetes. Atherosclerosis 2012;222:557-63. [PMID: 22572101 DOI: 10.1016/j.atherosclerosis.2012.03.034] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
14 Zhu J, O'Mara TA, Liu D, Setiawan VW, Glubb D, Spurdle AB, Fasching PA, Lambrechts D, Buchanan D, Kho PF, Cook LS, Friedenreich C, Lacey JV, Chen C, Wentzensen N, De Vivo I, Sun Y, Long J, Du M, Shu XO, Zheng W, Wu L, Yu H. Associations between Genetically Predicted Circulating Protein Concentrations and Endometrial Cancer Risk. Cancers (Basel) 2021;13:2088. [PMID: 33925895 DOI: 10.3390/cancers13092088] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Abd El Dayem SM, Battah AA, El Shehaby A, Abd Allah N. Assessment of human cartilage glycoprotein 39 (YKL-40), preptin, and nitric oxide in adolescent patients with type 1 diabetes and its relation to cardiorenal affection. J Pediatr Endocrinol Metab 2015;28:309-14. [PMID: 25719300 DOI: 10.1515/jpem-2014-0359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
16 Akboğa MK, Yalçın R, Şahinarslan A, Yılmaz Demirtaş C, Paşaoğlu H, Abacı A. Increased serum YKL-40 level is associated with the presence and severity of metabolic syndrome. Anatol J Cardiol 2016;16:953-8. [PMID: 27443476 DOI: 10.14744/AnatolJCardiol.2016.6933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
17 González-Muniesa P, Marrades MP, Martínez JA, Moreno-Aliaga MJ. Differential proinflammatory and oxidative stress response and vulnerability to metabolic syndrome in habitual high-fat young male consumers putatively predisposed by their genetic background. Int J Mol Sci 2013;14:17238-55. [PMID: 23975165 DOI: 10.3390/ijms140917238] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
18 Rodríguez A, Catalán V, Frühbeck G. Metabolism and satiety. Satiation, Satiety and the Control of Food Intake. Elsevier; 2013. pp. 75-111. [DOI: 10.1533/9780857098719.2.75] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Roca-Rivada A, Bravo SB, Pérez-Sotelo D, Alonso J, Castro AI, Baamonde I, Baltar J, Casanueva FF, Pardo M. CILAIR-Based Secretome Analysis of Obese Visceral and Subcutaneous Adipose Tissues Reveals Distinctive ECM Remodeling and Inflammation Mediators. Sci Rep 2015;5:12214. [PMID: 26198096 DOI: 10.1038/srep12214] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
20 Lee H, Kang R, Jee SH, Yoon Y. A promoter polymorphism −2122C>T of CHI3L1 is associated with serum low density lipoprotein cholesterol level in Korean subjects. Clinical Biochemistry 2010;43:1195-200. [DOI: 10.1016/j.clinbiochem.2010.07.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
21 Erfan G, Guzel S, Alpsoy S, Rifaioglu EN, Kaya S, Kucukyalcın V, Topcu B, Kulac M. Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis? Mol Cell Biochem 2015;400:207-12. [PMID: 25421412 DOI: 10.1007/s11010-014-2277-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
22 Vasquez MM, Hu C, Roe DJ, Chen Z, Halonen M, Guerra S. Least absolute shrinkage and selection operator type methods for the identification of serum biomarkers of overweight and obesity: simulation and application. BMC Med Res Methodol 2016;16:154. [PMID: 27842498 DOI: 10.1186/s12874-016-0254-8] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 9.0] [Reference Citation Analysis]
23 Vela D, Leshoski J, Vela Z, Jakupaj M, Mladenov M, Sopi RB. Insulin treatment corrects hepcidin but not YKL-40 levels in persons with type 2 diabetes mellitus matched by body mass index, waist-to-height ratio, C-reactive protein and Creatinine. BMC Endocr Disord 2017;17:53. [PMID: 28841871 DOI: 10.1186/s12902-017-0204-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Deng Y, Li G, Chang D, Su X. YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases. Clin Chim Acta 2020;511:40-6. [PMID: 33002471 DOI: 10.1016/j.cca.2020.09.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Teitsdottir UD, Arnardottir ES, Bjornsdottir E, Gislason T, Petersen PH. Obesity modulates the association between sleep apnea treatment and CHI3L1 levels but not CHIT1 activity in moderate to severe OSA: an observational study. Sleep Breath 2018;22:1101-9. [PMID: 30311184 DOI: 10.1007/s11325-018-1731-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
26 Li W, Yu Z, Jiang C. Association of Serum YKL-40 With the Presence and Severity of Obstructive Sleep Apnea Syndrome. Lab Med 2014;45:220-5. [DOI: 10.1309/lms98akcxrsl2xor] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Schernthaner G, Brix JM, Kopp HP, Schernthaner GH. Cure of type 2 diabetes by metabolic surgery? A critical analysis of the evidence in 2010. Diabetes Care 2011;34 Suppl 2:S355-60. [PMID: 21525482 DOI: 10.2337/dc11-s253] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
28 Liu Y, Liu SX, Cai Y, Xie KL, Zhang WL, Zheng F. Effects of combined aerobic and resistance training on the glycolipid metabolism and inflammation levels in type 2 diabetes mellitus. J Phys Ther Sci 2015;27:2365-71. [PMID: 26311110 DOI: 10.1589/jpts.27.2365] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
29 Mathiasen AB, Harutyunyan MJ, Jørgensen E, Helqvist S, Ripa R, Gøtze JP, Johansen JS, Kastrup J. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. Scandinavian Journal of Clinical and Laboratory Investigation 2011;71:439-47. [DOI: 10.3109/00365513.2011.586470] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
30 Brix J, Höllerl F, Koppensteiner R, Schernthaner G, Schernthaner G. YKL-40 in type 2 diabetic patients with different levels of albuminuria: YKL-40 IN TYPE 2 DIABETIC PATIENTS WITH DIFFERENT LEVELS OF ALBUMINURIA. European Journal of Clinical Investigation 2011;41:589-96. [DOI: 10.1111/j.1365-2362.2010.02446.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
31 Huang CJ, Slusher AL, Whitehurst M, Wells M, Maharaj A, Shibata Y. The impact of acute aerobic exercise on chitinase 3-like protein 1 and intelectin-1 expression in obesity. Exp Biol Med (Maywood) 2016;241:216-21. [PMID: 26316585 DOI: 10.1177/1535370215602785] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
32 Mygind ND, Harutyunyan MJ, Mathiasen AB, Ripa RS, Thune JJ, Gøtze JP, Johansen JS, Kastrup J; The CLARICOR Trial Group. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflamm Res 2011;60:281-7. [DOI: 10.1007/s00011-010-0266-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
33 Thomsen SB, Rathcke CN, Skaaby T, Linneberg A, Vestergaard H. The Association between genetic variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and the lipid profile in a Danish population. PLoS One 2012;7:e47094. [PMID: 23071724 DOI: 10.1371/journal.pone.0047094] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
34 Xu Y, Meng HL, Su YM, Chen C, Huang YH, Li XF, Fan MK, Yan YJ, Wu J, Jiang MH, Pan M. Serum YKL-40 is increased in patients with slow coronary flow. Coron Artery Dis 2015;26:121-5. [PMID: 25356814 DOI: 10.1097/MCA.0000000000000191] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
35 Womble JT, McQuade VL, Ihrie MD, Ingram JL. Imbalanced Coagulation in the Airway of Type-2 High Asthma with Comorbid Obesity. J Asthma Allergy 2021;14:967-80. [PMID: 34408442 DOI: 10.2147/JAA.S318017] [Reference Citation Analysis]
36 Höbaus C, Tscharre M, Herz CT, Pesau G, Wrba T, Koppensteiner R, Schernthaner GH. YKL-40 levels increase with declining ankle-brachial index and are associated with long-term cardiovascular mortality in peripheral arterial disease patients. Atherosclerosis 2018;274:152-6. [PMID: 29783062 DOI: 10.1016/j.atherosclerosis.2018.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
37 Aziz M, Wissing MLM, Naver KV, Faber J, Skouby SO. Polycystic ovary syndrome and low-grade inflammation with special reference to YKL-40. Gynecological Endocrinology 2013;30:311-5. [DOI: 10.3109/09513590.2013.879854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
38 Seyyedi J, Alizadeh S. Effect of Surgically Induced Weight Loss on Biomarkers of Endothelial Dysfunction: a Systematic Review and Meta-Analysis. OBES SURG 2020;30:3549-60. [DOI: 10.1007/s11695-020-04710-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Morimoto C, Matsumoto H, Tajiri T, Gon Y, Ito R, Hashimoto S, Suzukawa M, Ohta K, Izuhara K, Ono J, Ohta S, Ito I, Oguma T, Kanemitsu Y, Nagasaki T, Izuhara Y, Niimi A, Hirai T. High serum free IL-18 is associated with decreased omalizumab efficacy: findings from a 2-year omalizumab treatment study. J Asthma 2021;58:1133-42. [PMID: 32375555 DOI: 10.1080/02770903.2020.1766061] [Reference Citation Analysis]
40 Aam BB, Heggset EB, Norberg AL, Sørlie M, Vårum KM, Eijsink VG. Production of chitooligosaccharides and their potential applications in medicine. Mar Drugs 2010;8:1482-517. [PMID: 20559485 DOI: 10.3390/md8051482] [Cited by in Crossref: 382] [Cited by in F6Publishing: 337] [Article Influence: 31.8] [Reference Citation Analysis]
41 Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 2012;217:483-91. [DOI: 10.1016/j.imbio.2011.04.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
42 Cantó E, Tintoré M, Villar LM, Costa C, Nurtdinov R, Álvarez-cermeño JC, Arrambide G, Reverter F, Deisenhammer F, Hegen H, Khademi M, Olsson T, Tumani H, Rodríguez-martín E, Piehl F, Bartos A, Zimova D, Kotoucova J, Kuhle J, Kappos L, García-merino JA, Sánchez AJ, Saiz A, Blanco Y, Hintzen R, Jafari N, Brassat D, Lauda F, Roesler R, Rejdak K, Papuc E, de Andrés C, Rauch S, Khalil M, Enzinger C, Galimberti D, Scarpini E, Teunissen C, Sánchez A, Rovira A, Montalban X, Comabella M. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain 2015;138:918-31. [DOI: 10.1093/brain/awv017] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 13.9] [Reference Citation Analysis]
43 Mathiasen AB, Henningsen KMA, Harutyunyan MJ, Mygind ND, Kastrup J. YKL-40: a new biomarker in cardiovascular disease? Biomarkers in Medicine 2010;4:591-600. [DOI: 10.2217/bmm.10.58] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
44 Celik C, Abali R, Guzel S, Bastu E, Kucukyalcin V, Yilmaz M. Elevated circulating levels of YKL-40 are a marker of abnormal glucose tolerance in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012;77:893-7. [PMID: 22583189 DOI: 10.1111/j.1365-2265.2012.04437.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
45 Elhabak DM, Abdel Halim WA. YKL-40 A Sensitive Biomarker for Early Androgenetic Alopecia and Early Hidden Metabolic Syndrome. Int J Trichology 2020;12:49-55. [PMID: 32684675 DOI: 10.4103/ijt.ijt_100_19] [Reference Citation Analysis]
46 Li J, Niu G, Wang H, Wang K, Huang B, Li M. Serum YKL-40 levels in gestational diabetes mellitus. Gynecol Endocrinol 2016;32:412-5. [PMID: 26698539 DOI: 10.3109/09513590.2015.1126707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
47 Labrecque J, Laforest S, Michaud A, Biertho L, Tchernof A. Impact of Bariatric Surgery on White Adipose Tissue Inflammation. Canadian Journal of Diabetes 2017;41:407-17. [DOI: 10.1016/j.jcjd.2016.12.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
48 Baran A, Myśliwiec H, Szterling-Jaworowska M, Kiluk P, Świderska M, Flisiak I. Serum YKL-40 as a potential biomarker of inflammation in psoriasis. J Dermatolog Treat 2018;29:19-23. [PMID: 28498006 DOI: 10.1080/09546634.2017.1330529] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
49 Gybel-Brask D, Johansen JS, Christiansen IJ, Skibsted L, Høgdall EV. Serum YKL-40 and gestational diabetes - an observational cohort study. APMIS 2016;124:770-5. [PMID: 27457220 DOI: 10.1111/apm.12573] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
50 Rodríguez A, Ezquerro S, Méndez-Giménez L, Becerril S, Frühbeck G. Revisiting the adipocyte: a model for integration of cytokine signaling in the regulation of energy metabolism. Am J Physiol Endocrinol Metab 2015;309:E691-714. [PMID: 26330344 DOI: 10.1152/ajpendo.00297.2015] [Cited by in Crossref: 137] [Cited by in F6Publishing: 126] [Article Influence: 19.6] [Reference Citation Analysis]
51 Knøsgaard L, Thomsen SB, Støckel M, Vestergaard H, Handberg A. Circulating sCD36 is associated with unhealthy fat distribution and elevated circulating triglycerides in morbidly obese individuals. Nutr Diabetes 2014;4:e114. [PMID: 24710072 DOI: 10.1038/nutd.2014.11] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
52 Esteghamati A, Rezvani S, Khajeh E, Ebadi M, Nakhjavani M, Noshad S. Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial. J Endocrinol Invest 2014;37:1211-8. [PMID: 25138574 DOI: 10.1007/s40618-014-0154-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]